MedTrace Logo

Relative Bioavailability Among Different Eutropin Formulations

NCT03154840 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-07-21

No results posted yet for this study

Summary

1. Compares and evaluates the relative bioavailability of single-dose subcutaneous administration of each of the Eutropin formulations to healthy male volunteers.
2. Ensure safety and tolerability of single, subcutaneous administration of Eutropin formulations to healthy male volunteers.

Conditions

  • Relative Bioavailability

Interventions

DRUG

Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU

Investigate the Relative Bioavailability among Different Eutropin Formulations

Sponsors & Collaborators

  • LG Chem

    lead INDUSTRY

Principal Investigators

  • Kyun-Seop Bae · AIDS Malignancy Consortium

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-31
Primary Completion
2017-07-10
Completion
2017-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03154840 on ClinicalTrials.gov